retatrutide latest news ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial This New Retatrutide Update Can

December 2025: Biopharmaceutical firms intensified clinical trials for multi-target diabetes treatments combining glucose control with obesity and metabolic disorder management

The implications extend beyond obesity and diabetes to every class B GPCR target in the human genome, suggesting that many receptors previously considered "undruggable" by small molecules may be amenable to similar approaches

Total Vial Content: 10mg

The authors are fully responsible for the content and conclusions of the publication

Diabetes Care 2018

This project was realized with financial support of the project New Technologies for Translational Research in Pharmaceutical Sciences [NETPHARM, project ID CZ.02.01.01/00/22_008/0004607]co-funded by the European Union